E Fund Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$489K Sell
5,407
-345
-6% -$28.9K 0.01% 273
2026
Q1
$461K Buy
+5,752
New +$474K 0.01% 302
2025
Q2
$393K Sell
5,020
-802
-14% -$59.8K 0.02% 262
2025
Q1
$422K Sell
5,822
-24
-0.4% -$1.72K 0.02% 244
2024
Q4
$433K Buy
5,846
+2,273
+64% +$159K 0.02% 246
2024
Q3
$236K Buy
3,573
+681
+24% +$49.5K 0.01% 293
2024
Q2
$267K Buy
2,892
+22
+0.8% +$1.95K 0.01% 251
2024
Q1
$274K Sell
2,870
-63
-2% -$5.29K 0.02% 290
2023
Q4
$224K Buy
+2,933
New +$204K 0.01% 265
2023
Q3
Sell
-2,126
Closed -$201K 301
2023
Q2
$201K Sell
2,126
-323
-13% -$28.1K 0.02% 278
2023
Q1
$203K Buy
+2,449
New +$193K 0.01% 296
2022
Q4
Sell
-2,575
Closed -$213K 341
2022
Q3
$213K Buy
2,575
+278
+12% +$26.8K 0.02% 296
2022
Q2
$218K Buy
2,297
+39
+2% +$4.04K 0.02% 286
2022
Q1
$266K Sell
2,258
-127
-5% -$14.2K 0.01% 241
2021
Q4
$309K Sell
2,385
-30
-1% -$3.5K 0.01% 209
2021
Q3
$273K Buy
+2,415
New +$276K 0.01% 196

Other funds holding EW

E Fund Management's EW Position: Q2 2026 in Review

E Fund Management reduced its Edwards Lifesciences (EW) stake by 6% in Q2 2026, selling an estimated $28.9K and leaving 5,407 shares worth $489K. The position accounts for 0.01% of the portfolio, ranked #273.

E Fund Management first reported a position in EW in Q3 2021 and has held it in 16 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • E Fund Management held 5,407 shares of Edwards Lifesciences worth $489K as of Q2 2026.
  • E Fund Management sold 345 Edwards Lifesciences shares in Q2 2026, an estimated $28.9K.
  • Edwards Lifesciences made up 0.01% of E Fund Management's portfolio in Q2 2026, its #273 holding.
  • E Fund Management first reported a position in Edwards Lifesciences in Q3 2021 and has held it in 16 quarters since.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.